News

The new China facility is said to position Charles River as the strategic partner of choice to fully support clients’ global drug development needs. James Foster, president, chairman

The Phase I double-blind, placebo-controlled trial of CCX025 is being conducted in healthy male and female volunteers to evaluate the safety, tolerability and pharmacokinetics of CCX025 over a

New corporate investors Medtronic and Itochu join existing investors St Jude Medical, Adams Street Partners, The Carlyle Group, Essex Woodlands, Kaiser Permanente Ventures, Spring Ridge Ventures and others.

The study is largely funded by the National Institute on Drug Abuse and will be run jointly by the New York State Psychiatric Institute and Columbia University. The

The Phase IIa multi-center, open-label study enrolled 32 subjects and was conducted at 12 US sites. Study patients received 6R-BH4 at 2.5mg/kg, 5mg/kg, 10mg/kg and 20mg/kg for four

The project is sponsored by Simdat – a program funded by the European Commission under the Information Society Technologies Programme designed to test and enhance Grid data technology

Under the terms of the agreement, Miraculins will issue to Mount Sinai Hospital (MSH) 310,000 common shares from treasury, subject to a standard four-month and one day resale

Accell Evo3 is said to be the latest generation in demineralized bone matrix and is composed of an optimized blend of particulate demineralized bone matrix (DBM), the proprietary

Mr Hobbs is president and CEO of AngioDynamics, a medical device company specializing in the development and sales of medical technology serving the needs of interventional oncologists and